Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients.

OBJECTIVE We aimed at investigating the association of age-dependent IGF-I SDS with diabetes, dyslipidemia, hypertension, and heart diseases, in a large patient sample. BACKGROUND IGF-I has been suggested to be associated with several diseases and a prognostic marker for the development of cardiovascular diseases and risk factors. The findings, though, have been inconsistent possibly due to the methodological factors. METHODS We studied 6773 consecutive primary care patients, aged 18+ years, in a cross-sectional, epidemiological study in primary care, Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment study. All patients underwent a standardized clinical diagnostic and laboratory assessment. IGF-I levels were measured with an automated chemiluminescence assay system. We calculated the odds ratios (OR) for diseases in quintiles of IGF-I, and additionally analyzed the association of age-dependent IGF-I SDS with these conditions. RESULTS After multiple adjustments for confounders, we found increased ORs for coronary artery disease in patients with high IGF-I. Women, but not men, with low IGF-I also showed increased ORs for coronary artery disease. Dyslipidemia was positively associated with IGF-I. Type 2 diabetes showed a curvilinear association with IGF-I SDS. CONCLUSIONS The findings suggest the existence of multiple and complex interactions between IGF-I and several health conditions. The complex nature of disease- and subgroup-specific associations along with the methodological factors can be held responsible for divergent findings in previous studies.

[1]  P. Chanson,et al.  Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. , 2007, The Journal of clinical endocrinology and metabolism.

[2]  C. Massart,et al.  Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[3]  W. März,et al.  Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. , 2006, European journal of endocrinology.

[4]  S. Silber,et al.  Cardiovascular risk factors in primary care: methods and baseline prevalence rates – the DETECT program , 2005, Current medical research and opinion.

[5]  A. Giustina,et al.  Clinical review: Growth hormone and cardiovascular risk factors. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  G. Brabant,et al.  Applicability of recently established reference values for serum insulin-like growth factor 1: A comparison of two assays--an (automated) chemiluminescence immunoassay and an enzyme-linked immunosorbent assay. , 2005, Clinical laboratory.

[7]  A. von Eckardstein,et al.  Associations of insulin‐like growth factors, insulin‐like growth factor binding proteins and acid‐labile subunit with coronary heart disease , 2004, Clinical endocrinology.

[8]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[9]  E. Barrett-Connor,et al.  The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. , 2004, The Journal of clinical endocrinology and metabolism.

[10]  A. Juul.  Serum levels of insulin-like growth factor I and its binding proteins in health and disease. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[11]  G. Brabant,et al.  Serum Insulin-Like Growth Factor I Reference Values for an Automated Chemiluminescence Immunoassay System: Results from a Multicenter Study , 2003, Hormone Research in Paediatrics.

[12]  T. Jørgensen,et al.  Heart Disease : A Population-Based Case-Control Study Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic , 2002 .

[13]  D. Dunger,et al.  Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study , 2002, The Lancet.

[14]  Jeroen J. Bax,et al.  Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. , 2001, The Journal of clinical endocrinology and metabolism.

[15]  P. Poole‐Wilson,et al.  Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. , 2001, Journal of the American College of Cardiology.

[16]  S. Shalet,et al.  Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly , 2001, Annals of clinical biochemistry.

[17]  A. Hofman,et al.  A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. , 2001, Diabetes.

[18]  Growth Hormone Research Society,,et al.  Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society , 2001 .

[19]  R. Dietz,et al.  The somatotrophic system in patients with dilated cardiomyopathy: Relation of insulin‐like growth factor‐1 and its alterations during growth hormone therapy to cardiac function , 2000, Clinical endocrinology.

[20]  A. Hamsten,et al.  Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. , 2000, Journal of the American College of Cardiology.

[21]  A. Bayés‐Genís,et al.  The insulin-like growth factor axis: A review of atherosclerosis and restenosis. , 2000, Circulation research.

[22]  M. Thorén,et al.  Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. , 1999, The Journal of clinical endocrinology and metabolism.

[23]  M. Morello,et al.  Activity of GH/IGF‐I axis in patients with dilated cardiomyopathy , 1999, Journal of endocrinological investigation.

[24]  F. Follath,et al.  Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. , 1998, The Journal of clinical endocrinology and metabolism.

[25]  P. Poole‐Wilson,et al.  Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. , 1998, Journal of the American College of Cardiology.

[26]  P. Poole‐Wilson,et al.  Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy , 1998, The Lancet.

[27]  E. Ghigo,et al.  Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[29]  F. Minuto,et al.  Insulin-like growth factor-1 and angiographically documented coronary artery disease , 1996 .

[30]  F. Minuto,et al.  Insulin-like growth factor-I and angiographically documented coronary artery disease. , 1996, The American journal of cardiology.